Börse Express – EQS-News: MorphoSys AG: MorphoSys Expects Topline Results from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG: MorphoSys expects top-line results from the Phase 3 study of pelabresib in myelofibrosis in early 2024

EQS-News: MorphoSys AG / Key word(s): Conference

MorphoSys AG: MorphoSys expects top-line results from the phase 3 study

Pelabresib in myelofibrosis in early 2024

09.01.2023 / 07:01 CET/EST

The issuer / publisher is responsible for the content of the notification.

media release

Planegg/Munich, January 9, 2023

MorphoSys expects top-line results from phase 3 study with pelabresib

Myelofibrosis Anfang 2024

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that the

Top-line results expected from ongoing Phase 3 MANIFEST-2 study

Will be available in early 2024. MANIFEST-2 is a global,

randomized, double-blind phase 3 clinical trial evaluating the combination

of pelabresib, an investigational drug

BET inhibitor, in combination with ruxolitinib as first-line treatment

studied patients with myelofibrosis. The company had previously

informed that these data are expected in the first half of 2024

would. dr Jean-Paul Kress, Chief Executive Officer of MorphoSys, will

Wednesday, January 11, 2023 at 5:15 p.m. Pacific Time at 41st JP

Morgan Healthcare Conference in San Francisco for more news

Pelabresib and MorphoSys’s oncology pipeline.

“Patients with myelofibrosis respond to current first-line therapy

not sufficient and only for a limited time. The most recently featured

Phase 2 data suggests that pelabresib may have the potential to

to improve the current standard of care, which increases our confidence in the

Phase 3 MANIFEST-2 study strengthened,” says Dr. Jean-Paul Kress. “We are pleased

We look forward to sharing more news about pelabresib and our other clinical

programs during the JP Morgan Healthcare Conference.”

The live webcast of the presentation can be viewed on the MorphoSys website at

https://www.morphosys.com/en/investors. The presentation

and a replay of the webcast will also be available on

MorphoSys provided.

About MorphoSys

At MorphoSys we have a clear mission: we want people with cancer

enable a better and longer life. As a global, commercial

focused biopharmaceutical company, we use cutting-edge science and

Technologies to discover, develop and

to make available to patients. MorphoSys is headquartered in

Planegg, Germany and conducts its business in the USA from Boston,

Massachusetts. Visit www.morphosys.com for more information. consequences

us on LinkedIn and Twitter.

About Pelabresib

Pelabresib (CPI-0610) is a selective small molecule drug in the

Developmental phase characterized by inhibition of the function of BET proteins (BET

– bromodomain and extra terminal domain) promote anti-tumor activity

to increase the expression of abnormally expressed genes in cancer

to decrease. Pelabresib is currently used to treat myelofibrosis

examined and has not yet been examined by a regulatory authority or


About myelofibrosis

Myelofibrosis is a form of chronic leukemia that leads to a

extensive scarring of the bone marrow, reducing the normal

Production of healthy blood cells in the body is disturbed. The result is one

Reduction in red blood cells, leading to weakness and fatigue

may, as well as a reduction in blood platelets, increasing the risk of

Bleeding increased due to poor blood clotting. The myelofibrosis

is often associated with an enlarged spleen, which affects the quality of life

patients significantly affected. It is most common in people over

Diagnosed at the age of 50 and can be diagnosed independently (as primary myelofibrosis)

or as a result of another bone marrow disorder.


MANIFEST-2 (NCT04603495) is a global, double-blind, randomized

Phase 3 clinical trial of pelabresib in combination with ruxolitinib

versus placebo plus ruxolitinib in JAK inhibitor-naïve patients

myelofibrosis. The primary endpoint of the study is a reduction in

Spleen volume by at least 35% (SVR35) from baseline at 24

weeks. A key secondary endpoint of the study is improvement

Total Symptom Score (TSS50) by 50% or more vs

Baseline after 24 weeks. Constellation Pharmaceuticals, Inc., a

subsidiary of MorphoSys, is the sponsor of the MANIFEST-2 study.

Forward-Looking Statements

This release contains certain forward-looking statements about the

MorphoSys Group. The forward-looking statements contained herein

reflect MorphoSys’s assessment at the time of this announcement

and involves known and unknown risks and uncertainties

could cause actual results, financial condition and

the liquidity, performance or achievements of MorphoSys or the

Industry results significantly different from those in the forward-looking

Statements expressed or implied are historical or

future results, financial position and liquidity, performance

or deviate from the achievements. Even if the results, the performance, the

Financial position and liquidity of MorphoSys and the development of

Industry in which the company operates with these future-oriented

Statements are consistent, they cannot predict outcomes or

developments in future periods. Among the factors that

deviations can result. On the factors that lead to deviations

may include the fact that MorphoSys’s expectations may be wrong

could, the inherent uncertainties associated with

competitive developments, clinical trials and

product development activities and regulatory approval requirements,

MorphoSys’s dependence on collaborations with third parties that

Assessing the commercial potential of its development programs and

other risks identified in the risk factors in MorphoSys’s annual report

Form 20-F and others filed with the US Securities and Exchange Commission

documents are specified. Given these uncertainties, the reader is

advised not to rely on such forward-looking statements.

These forward-looking statements speak only as of the date of the

publication of this document. MorphoSys expressly disclaims any

undertakes no obligation to comply with any such forward-looking statements contained in this document

update to reflect changed expectations regarding it or changed

Events, conditions or circumstances on which any such statement is based

or which may affect the probability that the actual

results differ from those set forth in the forward-looking statements,

to reflect, unless expressly required to do so by law or

required by regulation.

For more information please contact:


Media contacts: Thomas Biegi Investor contacts: Dr. Julia

Vice President Tel.: +49 (0)89 Neugebauer Head of Investors

/ 89927 26079 Relations Tel: +49 (0)89 / 899 27 179

[1]thomas.biegi@morphosys.com [1]julia.neugebauer@morphosys.com 1.

1. mailto:julia.neugebauer@morphosys.com



Eamonn Nolan Director Tel: +1



01/09/2023 CET/CEST Publication of a corporate news/financial message,

transmitted by EQS News – a service of EQS Group AG.

The issuer / publisher is responsible for the content of the notification.

The EQS distribution services include statutory reporting obligations, corporate

News/financial news and press releases.

Media archive at https://eqs-news.com

Language: German

Company: MorphoSys AG

Semmelweisstr. 7

82152 Planegg


Phone: +49 (0)89 899 27-0

Fax: +49 (0)89 899 27-222

E-Mail: investors@morphosys.com

Internet: www.morphosys.com

ISIN: DE0006632003

WKN: 663200

Indices: SDAX, TecDAX

Stock exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Hamburg, Hanover,

Munich, Stuttgart, Tradegate Exchange; Nasdaq

EQS News ID: 1529819

End of message EQS News Service

1529819 09.01.2023 CET/CEST

 ISIN  DE0006632003

AXC0060 2023-01-09/09:05

Copyright dpa-AFX business news GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.